Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07047482
Recruiting Observational

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

NCT07047482 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Observational
Started
2025-05-01
Last updated
2025-07-10

Condition(s) studied

Colorectal Carcinoma

Investigational drug(s) / intervention(s)

Immunohistochemical staining

Immunohistochemical staining: Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.

Study summary

Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Specimens from patients with colorectal cancer. 2. Tissue blocks with sufficient material. 3. Specimens with sufficient clinical data. Exclusion Criteria: 1. Tissue blocks with insufficient, destroyed or necrotic material. 2. Specimens with insufficient clinical data.

Primary outcome measure(s)

  • Evaluation of p16 Expression in Colorectal Carcinoma. — 6 months
    Immunohistochemical staining of Colorectal tissues by p16 monoclonal antibody

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine Sohag Recruiting Recruiting

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon
Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting
Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting
Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon
Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047482 on ClinicalTrials.gov ↗ ← All trials in Egypt